Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | The MURANO study: key findings

John Seymour • 23 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Bendamustine Rituximab Venetoclax
MURANO

John Seymour, MBBS, PhD, Peter MacCallum Cancer Center, Melbourne, Australia discusses the biological subsets, safety analysis and serial measurable residual disease (MRD) within the MURANO study (NCT02005471). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from John Seymour

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:18
Efficacy of subsequent therapies for CLL patients treated in the MURANO trial
John Seymour • 8 Dec 2023
3:54
CLL advances: What will we see more of in 2021?
John Seymour • 7 Dec 2020
8:04
The MURANO study in CLL: 5 years on
John Seymour • 7 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals